CN104491766B - One treats melanomatous Chinese medicine composition and preparation method thereof - Google Patents

One treats melanomatous Chinese medicine composition and preparation method thereof Download PDF

Info

Publication number
CN104491766B
CN104491766B CN201510042242.1A CN201510042242A CN104491766B CN 104491766 B CN104491766 B CN 104491766B CN 201510042242 A CN201510042242 A CN 201510042242A CN 104491766 B CN104491766 B CN 104491766B
Authority
CN
China
Prior art keywords
parts
radix
chinese medicine
medicine composition
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201510042242.1A
Other languages
Chinese (zh)
Other versions
CN104491766A (en
Inventor
李绵利
董艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Li Mianli
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510042242.1A priority Critical patent/CN104491766B/en
Publication of CN104491766A publication Critical patent/CN104491766A/en
Application granted granted Critical
Publication of CN104491766B publication Critical patent/CN104491766B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/344—Codonopsis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8984—Dendrobium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8988—Gastrodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Abstract

The invention belongs to the field of Chinese medicines, relate to one and treat melanomatous Chinese medicine composition and preparation method thereof.Comparatively large to the side effect of melanoma patients in order to overcome chemotherapy course in prior art, the invention provides one and can treat melanomatous Chinese medicine composition, it prepares primarily of kinds of traditional Chinese medicines such as Radix Et Caulis Acanthopanacis Senticosi, Radix Codonopsis, Fructus Crataegi, Radix Sanguisorbaes.Can significantly check melanin tumor cell proliferation and cell death inducing when it is treated for melanoma, and side effects of pharmaceutical drugs are low, are applicable to being developed to melanoma medicine.

Description

One treats melanomatous Chinese medicine composition and preparation method thereof
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to one and be used for the treatment of melanomatous Chinese medicine composition and preparation method thereof.
Background technology
Malignant melanoma is the tumor produced by skin and other organ melanocytes.Cutaneous melanoma shows as pigmentosa skin lesion and occurs obviously to change in several months or several years.Though its sickness rate is low, its grade of malignancy is high, and transfer occurs early, and mortality rate is high, and therefore early diagnosis, early treatment are very important.Malignant melanoma betides adult mostly, and the case of huge property congenital nevus cell nevus secondary canceration is more common in child.Melanoma etiology is illustrated not yet completely.Some research datas are pointed out, and its generation is relevant with following risk factor: gene, environment and gene/environment common factor.Such as be not true to type that (dysplasia) nevus or melanoma family history, photoconduction cause Pigmented skin, are not easy tanning, red hair ethnic group, strong interruption Sunlight exposure, sunburn, multiple melanocytic naevi etc.Gene/environment many factors causes Melanoma Malignant to transform.The key cells path of vicious transformation: Rb path, p53 path, PI3K/AKT path, RAS/MAPK path (20 ~ 30%NRAS suddenlys change, and 55 ~ 60%BRAF suddenlys change).
The clinical symptoms of CMM, comprise hemorrhage, pruritus, tenderness, ulcer etc., in general, melanomatous symptom is relevant to age of onset, young patient generally shows as pruritus, the color of skin lesion changes and boundary expands, gerontal patient generally shows as skin lesion and occurs ulcer, usually points out prognosis mala.The skin lesion performance of CMM is relevant to the growth pattern of the region of anatomy and tumor, namely relevant to histological type, and histological type has very big-difference because of the difference of age, type, race again.Dissimilar melanoma has the different causes of disease and genetic background, and current melanomatous clinical tissue credit type adopts Clark typing, comprises four types: lentigo maligna melanoma (LMM); Superficial spreading melanoma; Acra freckle sample melanoma/mucosal melanoma; Nodular melanoma (NM).In the white people suffering from malignant melanoma, about 70% is SSM.But in the Aisan of all malignant melanomas, the ALM betiding less sun exposure position accounts for 72%.
Clinical is at present answer excision to the infringement do not shifted in early days for melanomatous Therapeutic Principle, the scope of excising skin lesion periphery normal skin should be determined according to the Breslow degree of depth, if refer to (toe) malignant melanoma, can adopt and cut finger (toe) art.Involved lymph nodes should be excised, but preventative lymph node resection is still disputable.Perfusion of limb anti-mitosis medicine treatment limbs melanoma has certain curative effect.Although biochemotherapy and molecular targeted therapy have very large prospect, combined chemotherapy and radiotherapy is adopted to be still topmost therapeutic modality for the melanoma patients that extensively transfer occurs.The present invention aims to provide a kind of determined curative effect and the low melanoma medicine of toxic and side effects.
In prior art, chemotherapy course is comparatively large to the side effect of melanoma patients, and can not be satisfactory for killing of melanoma cell.In order to overcome above-mentioned the deficiencies in the prior art, the object of this invention is to provide one and can treat melanomatous Chinese medicine composition, it significantly can kill melanoma cell, is applicable to being developed to melanoma medicine.
One treats melanomatous Chinese medicine composition, it is made up of the raw material of following weight: Radix Et Caulis Acanthopanacis Senticosi 8-20 part, Radix Codonopsis 5-15 part, Fructus Crataegi 5-15 part, Radix Sanguisorbae 3-10 part, Herba Agrimoniae 10-25 part, Herba Epimedii 5-15 part, Rhizoma Coptidis 10-20 part, Chinese Radix Scutellariae 3-10 part, Caulis Akebiae 10-20 part, Cortex Phellodendri 8-20 part, Radix Polygoni Multiflori Preparata 5-12 part, Fructus Lycii 10-20 part, Rhizoma Anemarrhenae 3-10 part, Rhizoma Curcumae Longae 5-15 part, Semen Euryales 3-10 part, Herba Dendrobii 3-10 part, Radix Achyranthis Bidentatae 5-12 part, Galla Chinensis 10-15 part, Radix Angelicae Sinensis 10-20 part, Cortex Magnoliae Officinalis 3-10 part, Radix Astragali 5-15 part, Flos Lonicerae 5-15 part, Rhizoma Gastrodiae 5-25 part, Poria 10-20 part,
The above-mentioned Chinese medicine of the present invention is clinical conventional Chinese medicine, and its medicinal part is well known to the skilled person, and described Chinese medicine composition significantly can alleviate the toxic and side effects in melanoma therapeutic process after reasonable compatibility, and heightens the effect of a treatment.Reinforced effects melanoma cell in melanoma medicine or radiation therapy process killed according to Chinese medicine composition and the difference alleviating effect for toxic and side effects in therapeutic process, inventor is preferably as follows on above-mentioned Chinese medicine composition basis:
(1) Radix Et Caulis Acanthopanacis Senticosi 15 parts, Radix Codonopsis 10 parts, Fructus Crataegi 10 parts, Radix Sanguisorbae 7 parts, Herba Agrimoniae 18 parts, Herba Epimedii 10 parts, Rhizoma Coptidis 15 parts, Chinese Radix Scutellariae 7 parts, Caulis Akebiae 15 parts, Cortex Phellodendri 14 parts, Radix Polygoni Multiflori Preparata 9 parts, Fructus Lycii 15 parts, the Rhizoma Anemarrhenae 7 parts, 10 parts, Rhizoma Curcumae Longae, Semen Euryales 7 parts, Herba Dendrobii 6 parts, Radix Achyranthis Bidentatae 8 parts, Galla Chinensis 13 parts, Radix Angelicae Sinensis 15 parts, Cortex Magnoliae Officinalis 7 parts, the Radix Astragali 10 parts, Flos Lonicerae 10 parts, 20 parts, Rhizoma Gastrodiae, 15 parts, Poria.
(2) Radix Et Caulis Acanthopanacis Senticosi 8 parts, Radix Codonopsis 5 parts, Fructus Crataegi 5 parts, Radix Sanguisorbae 3 parts, Herba Agrimoniae 10 parts, Herba Epimedii 5 parts, Rhizoma Coptidis 10 parts, Chinese Radix Scutellariae 3 parts, Caulis Akebiae 10 parts, Cortex Phellodendri 8 parts, Radix Polygoni Multiflori Preparata 5 parts, Fructus Lycii 10 parts, the Rhizoma Anemarrhenae 3 parts, 5 parts, Rhizoma Curcumae Longae, Semen Euryales 3 parts, Herba Dendrobii 3 parts, Radix Achyranthis Bidentatae 5 parts, Galla Chinensis 10 parts, Radix Angelicae Sinensis 10 parts, Cortex Magnoliae Officinalis 3 parts, the Radix Astragali 5 parts, Flos Lonicerae 5 parts, 5 parts, Rhizoma Gastrodiae, 10 parts, Poria.
(3) Radix Et Caulis Acanthopanacis Senticosi 20 parts, Radix Codonopsis 15 parts, Fructus Crataegi 15 parts, Radix Sanguisorbae 10 parts, Herba Agrimoniae 25 parts, Herba Epimedii 15 parts, Rhizoma Coptidis 20 parts, Chinese Radix Scutellariae 10 parts, Caulis Akebiae 20 parts, Cortex Phellodendri 20 parts, Radix Polygoni Multiflori Preparata 12 parts, Fructus Lycii 20 parts, the Rhizoma Anemarrhenae 10 parts, 15 parts, Rhizoma Curcumae Longae, Semen Euryales 10 parts, Herba Dendrobii 10 parts, Radix Achyranthis Bidentatae 12 parts, Galla Chinensis 15 parts, Radix Angelicae Sinensis 20 parts, Cortex Magnoliae Officinalis 10 parts, the Radix Astragali 15 parts, Flos Lonicerae 15 parts, 25 parts, Rhizoma Gastrodiae, 20 parts, Poria.
Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, mixture, tablet or capsule.The present invention also provides a kind of preparation method of above-mentioned Chinese medicine composition, it comprises the steps: that getting recipe quantity Chinese crude drug is broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in the melanomatous medicine of preparation treatment.Chinese medicine composition of the present invention has the effect of remarkable check melanin tumor cell proliferation and cell death inducing, the embodiment of the present invention 6 shows, Chinese medicine composition of the present invention is external all shows stronger inhibitory action to three kinds of melanoma cell strain (B16, A375 and SK-MEL-2) cell proliferation, the most remarkable with 25-100mg/mL concentration.Adopt AnnexinV and PI two dye Flow cytometry to show, Chinese medicine composition of the present invention shows stronger cell death inducing effect to human melanoma cell strain A375, is suitable for being developed to melanoma medicine.
Chinese medicine composition of the present invention, in treatment melanoma, compared with prior art has following advantage:
1) compared with current black element tumor medicine, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, significantly improve the compliance of melanoma patients, and improve the quality of life of patient.
2) in Chinese medicine composition of the present invention containing multi-medicament component, action target spot is numerous, and pharmacological evaluation shows it and has the effect significantly reducing toxic and side effects in chemotherapy process, improves its melanoma inhibition to melanoma cell.
Summary of the invention
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
(1) example of formulations part
Embodiment 1 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Radix Et Caulis Acanthopanacis Senticosi 80g, Radix Codonopsis 50g, Fructus Crataegi 50g, Radix Sanguisorbae 30g, Herba Agrimoniae 100g, Herba Epimedii 50g, Rhizoma Coptidis 100g, Chinese Radix Scutellariae 30g, Caulis Akebiae 100g, Cortex Phellodendri 80g, Radix Polygoni Multiflori Preparata 50g, Fructus Lycii 100g, Rhizoma Anemarrhenae 30g, Rhizoma Curcumae Longae 50g, Semen Euryales 30g, Herba Dendrobii 30g, Radix Achyranthis Bidentatae 50g, Galla Chinensis 100g, Radix Angelicae Sinensis 100g, Cortex Magnoliae Officinalis 30g, Radix Astragali 50g, Flos Lonicerae 50g, Rhizoma Gastrodiae 50g, Poria 100g;
Preparation method: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 4 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40%, reflux, extract, three times, return time is 5h, filters, and filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
Embodiment 2 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Radix Et Caulis Acanthopanacis Senticosi 200g, Radix Codonopsis 150g, Fructus Crataegi 150g, Radix Sanguisorbae 100g, Herba Agrimoniae 250g, Herba Epimedii 150g, Rhizoma Coptidis 200g, Chinese Radix Scutellariae 100g, Caulis Akebiae 200g, Cortex Phellodendri 200g, Radix Polygoni Multiflori Preparata 120g, Fructus Lycii 200g, Rhizoma Anemarrhenae 100g, Rhizoma Curcumae Longae 150g, Semen Euryales 100g, Herba Dendrobii 100g, Radix Achyranthis Bidentatae 120g, Galla Chinensis 150g, Radix Angelicae Sinensis 200g, Cortex Magnoliae Officinalis 100g, Radix Astragali 150g, Flos Lonicerae 150g, Rhizoma Gastrodiae 250g, Poria 200g;
Preparation method: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 90%, reflux, extract, three times, return time is 3h, filters, and filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
Embodiment 3 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Radix Et Caulis Acanthopanacis Senticosi 150g, Radix Codonopsis 100g, Fructus Crataegi 100g, Radix Sanguisorbae 70g, Herba Agrimoniae 180g, Herba Epimedii 100g, Rhizoma Coptidis 150g, Chinese Radix Scutellariae 70g, Caulis Akebiae 150g, Cortex Phellodendri 140g, Radix Polygoni Multiflori Preparata 90g, Fructus Lycii 150g, Rhizoma Anemarrhenae 70g, Rhizoma Curcumae Longae 100g, Semen Euryales 70g, Herba Dendrobii 60g, Radix Achyranthis Bidentatae 80g, Galla Chinensis 130g, Radix Angelicae Sinensis 150g, Cortex Magnoliae Officinalis 70g, Radix Astragali 100g, Flos Lonicerae 100g, Rhizoma Gastrodiae 200g, Poria 150g;
Preparation method: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 70%, reflux, extract, three times, return time is 4h, filters, and filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Chinese medical concrete is pulverized and adds preparation and commonly use adjuvant and be prepared into tablet or capsule.
Embodiment 4 Chinese medicine composition of the present invention and preparation technology
Prescription is composed as follows: Radix Et Caulis Acanthopanacis Senticosi 80g, Radix Codonopsis 150g, Fructus Crataegi 150g, Radix Sanguisorbae 30g, Herba Agrimoniae 250g, Herba Epimedii 150g, Rhizoma Coptidis 100g, Chinese Radix Scutellariae 100g, Caulis Akebiae 100g, Cortex Phellodendri 160g, Radix Polygoni Multiflori Preparata 120g, Fructus Lycii 100g, Rhizoma Anemarrhenae 30g, Rhizoma Curcumae Longae 50g, Semen Euryales 100g, Herba Dendrobii 100g, Radix Achyranthis Bidentatae 70g, Galla Chinensis 100g, Radix Angelicae Sinensis 150g, Cortex Magnoliae Officinalis 30g, Radix Astragali 100g, Flos Lonicerae 100g, Rhizoma Gastrodiae 100g, Poria 100g;
Preparation method: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 70%, reflux, extract, three times, return time is 4h, filters, and filtrate reclaims ethanol after merging, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Adding ethanol to alcohol content is 75% (v/v), leaves standstill 24 hours, gets supernatant, and reclaim ethanol and concentrate, add water to 1000ml, stir evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
Embodiment 5
Prescription is composed as follows: Radix Et Caulis Acanthopanacis Senticosi 140g, Radix Codonopsis 100g, Fructus Crataegi 130g, Radix Sanguisorbae 60g, Herba Agrimoniae 200g, Herba Epimedii 150g, Rhizoma Coptidis 200g, Chinese Radix Scutellariae 30g, Caulis Akebiae 160g, Cortex Phellodendri 110g, Radix Polygoni Multiflori Preparata 70g, Fructus Lycii 160g, Rhizoma Anemarrhenae 70g, Rhizoma Curcumae Longae 110g, Semen Euryales 50g, Herba Dendrobii 100g, Radix Achyranthis Bidentatae 120g, Galla Chinensis 150g, Radix Angelicae Sinensis 160g, Cortex Magnoliae Officinalis 100g, Radix Astragali 150g, Flos Lonicerae 120g, Rhizoma Gastrodiae 180g, Poria 170g;
Preparation technology is with embodiment 4.
(2) test examples part
Embodiment 6: Chinese medicine composition of the present invention is to the inhibitory action of melanoma cell strain
1, cell strain: mouse melanin tumor cell strain (B16), purchased from Chinese Academy of Sciences's Shanghai cell bank.Human melanoma cell strain (A375 and SK-MEL-2) is purchased from ATCC.Above-mentioned cell strain with the DMEM culture medium containing 10% hyclone 37 DEG C, volume fraction be 5%CO2, completely saturated humidity condition under cellar culture, 48h replaced medium, when Growth of Cells reaches full conjunction state, by 0.25% trypsin+0.02%EDTA had digestive transfer culture, 2 ~ 3d goes down to posterity 1 time, and exponential phase cell is selected in experiment.
2, the detection of cell proliferation:
Adjusting B16, A375 and SK-MEL-2 cell strain concentration of cell suspension is respectively 1 × 105/mL, adds in 96 well culture plates, every hole 100 μ L, puts 37 DEG C of 5%CO2 incubators and cultivates 24h.Absorb old culture medium, (drug level is 100mg/mL, 50mg/mL to the plasma-free DMEM medium adding containing Chinese medicine composition of the present invention respectively, 25mg/mL, 5mg/mL), and establish blank group and zeroing group, often organize and all establish 3 multiple holes, continue to cultivate 24h.Add 10 μ LWST-8 solution, cultivate 2h.The light absorption value in each hole is detected at 490nm place.Cell proliferation inhibition rate=(1-(dosing group OD meansigma methods-zeroing hole OD meansigma methods)/(blank group OD meansigma methods-zeroing hole OD meansigma methods)) × 100%.Experiment repetition more than 3 times.
3, apoptotic detection
Adjustment A375 concentration of cell suspension is 1 × 106/mL, cell is inoculated in 6 orifice plates, every hole 1ml.Reach after Fusion Strain until Growth of Cells, former culture medium is abandoned in suction, add containing Chinese medicine composition of the present invention that (drug level is 100mg/mL respectively, 50mg/mL, 25mg/mL, plasma-free DMEM medium 5mg/mL), blank group adds the culture medium containing 0.1%DMSO, after drug effect 24h, cell conditioned medium is drawn in centrifuge tube, cell is after trypsinization, move in the centrifuge tube identical with cell conditioned medium, 1000rpm4 DEG C of centrifugal 5min, abandon supernatant, 1 time is washed with PBS, abandon supernatant, 1 time is washed with Binding buffer, and it is resuspended with 195 μ L Binding buffer, after 5 μ L Annexin V-FITC mix, room temperature lucifuge hatches 10 minutes, 1 time is washed with Binding buffer, and it is resuspended with 190 μ L Binding buffer, add 10 μ LPI and mix machine testing on rear flow cytometer.
4 experimental results
The testing result that 4.1 Chinese medicine compositions of the present invention affect three kinds of melanoma cell strain cell proliferation
The testing result that table 1 Chinese medicine composition of the present invention affects three kinds of melanoma cell strain cell proliferation
Drug level B16 cell inhibitory rate A375 cell inhibitory rate SK-MEL-2 cell inhibitory rate
5mg/mL 21.5％ 16.8％ 29.4％
25mg/mL 57.6％ 56.2％ 46.8％
50mg/mL 68.6％ 76.9％ 60.4％
100mg/mL 79.8％ 95.8％ 86.7％
WST-8 is the method detecting cell proliferation and toxicity comparatively advanced person.This experimental result shows, and Chinese medicine composition of the present invention is external all shows stronger inhibitory action to three kinds of melanoma cell strain (B16, A375 and SK-MEL-2) cell proliferation, the most remarkable with 25-100mg/mL concentration.
4.2, Chinese medicine composition of the present invention is to the testing result of human melanoma cell strain A375 Apoptosis
AnnexinV and PI two dye Flow cytometry is adopted to show, Chinese medicine composition of the present invention shows stronger cell death inducing effect to human melanoma cell strain A375, be 100mg/mL at drug level, 50mg/mL, in the culture medium of 25mg/mL, 5mg/mL, the apoptosis rate of A375 cell strain is respectively 85%, 90%, 25% and 15% is the most remarkable with 50-100mg/mL concentration.

Claims (7)

1. the melanomatous Chinese medicine composition for the treatment of, it is characterized in that, described Chinese medicine composition is obtained by the raw material of following weight portion: Radix Et Caulis Acanthopanacis Senticosi 8-20 part, Radix Codonopsis 5-15 part, Fructus Crataegi 5-15 part, Radix Sanguisorbae 3-10 part, Herba Agrimoniae 10-25 part, Herba Epimedii 5-15 part, Rhizoma Coptidis 10-20 part, Chinese Radix Scutellariae 3-10 part, Caulis Akebiae 10-20 part, Cortex Phellodendri 8-20 part, Radix Polygoni Multiflori Preparata 5-12 part, Fructus Lycii 10-20 part, Rhizoma Anemarrhenae 3-10 part, Rhizoma Curcumae Longae 5-15 part, Semen Euryales 3-10 part, Herba Dendrobii 3-10 part, Radix Achyranthis Bidentatae 5-12 part, Galla Chinensis 10-15 part, Radix Angelicae Sinensis 10-20 part, Cortex Magnoliae Officinalis 3-10 part, Radix Astragali 5-15 part, Flos Lonicerae 5-15 part, Rhizoma Gastrodiae 5-25 part, Poria 10-20 part.
2. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition is obtained by the raw material of following weight portion: Radix Et Caulis Acanthopanacis Senticosi 15 parts, Radix Codonopsis 10 parts, Fructus Crataegi 10 parts, Radix Sanguisorbae 7 parts, Herba Agrimoniae 18 parts, Herba Epimedii 10 parts, Rhizoma Coptidis 15 parts, Chinese Radix Scutellariae 7 parts, Caulis Akebiae 15 parts, Cortex Phellodendri 14 parts, Radix Polygoni Multiflori Preparata 9 parts, Fructus Lycii 15 parts, the Rhizoma Anemarrhenae 7 parts, 10 parts, Rhizoma Curcumae Longae, Semen Euryales 7 parts, Herba Dendrobii 6 parts, Radix Achyranthis Bidentatae 8 parts, Galla Chinensis 13 parts, Radix Angelicae Sinensis 15 parts, Cortex Magnoliae Officinalis 7 parts, the Radix Astragali 10 parts, Flos Lonicerae 10 parts, 20 parts, Rhizoma Gastrodiae, 15 parts, Poria.
3. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition is obtained by the raw material of following weight portion: Radix Et Caulis Acanthopanacis Senticosi 8 parts, Radix Codonopsis 5 parts, Fructus Crataegi 5 parts, Radix Sanguisorbae 3 parts, Herba Agrimoniae 10 parts, Herba Epimedii 5 parts, Rhizoma Coptidis 10 parts, Chinese Radix Scutellariae 3 parts, Caulis Akebiae 10 parts, Cortex Phellodendri 8 parts, Radix Polygoni Multiflori Preparata 5 parts, Fructus Lycii 10 parts, the Rhizoma Anemarrhenae 3 parts, 5 parts, Rhizoma Curcumae Longae, Semen Euryales 3 parts, Herba Dendrobii 3 parts, Radix Achyranthis Bidentatae 5 parts, Galla Chinensis 10 parts, Radix Angelicae Sinensis 10 parts, Cortex Magnoliae Officinalis 3 parts, the Radix Astragali 5 parts, Flos Lonicerae 5 parts, 5 parts, Rhizoma Gastrodiae, 10 parts, Poria.
4. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition is obtained by the raw material of following weight portion: Radix Et Caulis Acanthopanacis Senticosi 20 parts, Radix Codonopsis 15 parts, Fructus Crataegi 15 parts, Radix Sanguisorbae 10 parts, Herba Agrimoniae 25 parts, Herba Epimedii 15 parts, Rhizoma Coptidis 20 parts, Chinese Radix Scutellariae 10 parts, Caulis Akebiae 20 parts, Cortex Phellodendri 20 parts, Radix Polygoni Multiflori Preparata 12 parts, Fructus Lycii 20 parts, the Rhizoma Anemarrhenae 10 parts, 15 parts, Rhizoma Curcumae Longae, Semen Euryales 10 parts, Herba Dendrobii 10 parts, Radix Achyranthis Bidentatae 12 parts, Galla Chinensis 15 parts, Radix Angelicae Sinensis 20 parts, Cortex Magnoliae Officinalis 10 parts, the Radix Astragali 15 parts, Flos Lonicerae 15 parts, 25 parts, Rhizoma Gastrodiae, 20 parts, Poria.
5. the Chinese medicine composition as described in as arbitrary in claim 1-4, it is characterized in that, described Chinese medicine composition is powder, mixture, tablet or capsule.
6. prepare the method for the arbitrary described Chinese medicine composition of claim 1-4 for one kind, it is characterized in that, described preparation method comprises the steps: that getting recipe quantity Chinese crude drug is broken into coarse powder, adds according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filter, filtrate reclaims ethanol, cold filtration after merging, wash with water, after drying, namely obtain Chinese medical concrete; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically in this preparation method.
7. the purposes of the arbitrary described Chinese medicine composition of claim 1-4 in the melanomatous medicine of preparation treatment.
CN201510042242.1A 2015-01-27 2015-01-27 One treats melanomatous Chinese medicine composition and preparation method thereof Expired - Fee Related CN104491766B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510042242.1A CN104491766B (en) 2015-01-27 2015-01-27 One treats melanomatous Chinese medicine composition and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510042242.1A CN104491766B (en) 2015-01-27 2015-01-27 One treats melanomatous Chinese medicine composition and preparation method thereof

Publications (2)

Publication Number Publication Date
CN104491766A CN104491766A (en) 2015-04-08
CN104491766B true CN104491766B (en) 2015-08-26

Family

ID=52933280

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510042242.1A Expired - Fee Related CN104491766B (en) 2015-01-27 2015-01-27 One treats melanomatous Chinese medicine composition and preparation method thereof

Country Status (1)

Country Link
CN (1) CN104491766B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106869A (en) * 2015-09-30 2015-12-02 青岛友诚高新技术有限公司 Traditional Chinese medicine composition for treating melanoma and preparation method of traditional Chinese medicine composition
CN105193715B (en) * 2015-10-23 2017-12-12 云南云龙制药股份有限公司 A kind of preparation method and application of Torvosaurus liquid
CN105497810A (en) * 2016-01-20 2016-04-20 青岛云天生物技术有限公司 Pharmaceutical composition for treating malignant melanoma and application thereof
KR101899122B1 (en) * 2017-04-20 2018-09-21 주식회사 제넨셀 Pharmaceutical composition for preventing or treating hepatitis C virus infectious disease
CN107137671A (en) * 2017-07-13 2017-09-08 中国人民解放军第三军医大学 It is a kind of to treat pharmaceutical composition of melanoma and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858953B2 (en) * 2011-05-09 2014-10-14 Yu-Hwa Peter Sheng Herbal composition for treating cancer

Also Published As

Publication number Publication date
CN104491766A (en) 2015-04-08

Similar Documents

Publication Publication Date Title
WO2014139282A1 (en) Pharmaceutical compositions for treating cancer of genital system and preparation method therefor
CN104491766B (en) One treats melanomatous Chinese medicine composition and preparation method thereof
CN102078569B (en) Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof
CN105169143B (en) A kind of Chinese medicine composition treating melanoma and preparation method thereof
CN103157014B (en) Miao medicine for treating tumors
CN104435686A (en) Use of traditional Chinese medicine preparation in preparation of medicine for treating skin itch and eczema papulosum
CN109549958B (en) Composition for treating hormone-dependent dermatitis and preparation method thereof
CN103830527A (en) Preparation for treating prostatitis
CN111481638A (en) Traditional Chinese medicine enema preparation for treating ulcerative colitis and preparation method thereof
CN102579999A (en) Medicine for treating carcinous fever and preparation method thereof
CN103536850A (en) Traditional Chinese medicine for treating verruca plana from inside and outside
CN113769003A (en) Medicine for treating hyperplasia of mammary glands and breast tumor and preparation method thereof
CN106309749A (en) Traditional Chinese medicine for treating cervical cancer
WO2016165495A1 (en) Topical medicine for treating lung cancer and preparation method thereof
CN105012552A (en) Traditional Chinese medicine for treating wind-prevailing migratory arthralgia type rheumatic arthritis and preparation method
CN104888149A (en) Drug for treating cervical cancer and preparation method for drug
CN105106634A (en) Traditional Chinese medicine preparation for treating acute appendicitis and application thereof
CN103055094B (en) Traditional Chinese medicine for treating leukemia and preparation method thereof
CN114869987B (en) Traditional Chinese medicine composition for preventing liver cancer
CN106421074A (en) Traditional Chinese medicine composition with anti-cancer and anti-tumor functions and preparation method thereof
CN105497810A (en) Pharmaceutical composition for treating malignant melanoma and application thereof
CN103623354B (en) Traditional Chinese medicinal preparation for treating retroperitoneal follicular dendritic cell sarcoma
CN105456444A (en) Chinese herbal preparation for treating melanoma and preparation method and application thereof
CN105311469A (en) Anticancer preparation and preparing method thereof
CN105125714A (en) Traditional Chinese medicine preparation for treating chemotherapeutic phlebitis and preparing method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: LI MIANLI

Free format text: FORMER OWNER: ZOU SHIDONG

Effective date: 20150722

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Li Mianli

Inventor after: Dong Yan

Inventor before: Hu Xuerong

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: HU XUERONG TO: LI MIANLI DONG YAN

TA01 Transfer of patent application right

Effective date of registration: 20150722

Address after: 256600, No. two, 661 the Yellow River Road, Bincheng District, Shandong, Binzhou

Applicant after: Li Mianli

Address before: Qin village 277799 Shandong city of Linyi province Lanling County No. 149 Bian Zhen

Applicant before: Zou Shidong

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150826

Termination date: 20160127

EXPY Termination of patent right or utility model